Full text is available at the source.
Abstract
Evidence-based recommendations are provided for selecting injectable therapies in adults with type 2 diabetes who do not adequately respond to GLP-1 receptor agonists.
- Injectable therapies beyond GLP-1 receptor agonists may be necessary for patients with type 2 diabetes who do not achieve optimal blood sugar control.
- The guideline emphasizes the importance of individualizing treatment choices based on patient characteristics and clinical needs.
- The recommendations focus on enhancing treatment efficacy and addressing safety concerns associated with additional injectable medications.
Simplified